TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21121981
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) 5.0 × 10⁷ CFU/g, daily intake of 3.4 × 10⁹ CFU for 3 months
Study: 17451506
Drug: Amine fluoride/stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse used daily for 3 weeks
Study: 11386644
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/mL applied intraoperatively for 5 minutes)
Study: 8038981
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol 10 mg (group I)
Study: 8038981
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml intralipid (group II)
Study: 2740681
Drug: Single-dose Ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Ceftriaxone (2 grams)
Study: 2740681
Drug: Cefamandole (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (multiple doses)
Study: 1221098
Drug: Drug induced
Normalized name: Drug induced platelet antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug induced hypotension
Study: 1221098
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (drug induced hypotension and antifibrinolytic therapy)
Study: 31521682
Drug: CABG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG + optimal medical therapy
Study: 25290104
Drug: Cycloidal vibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloidal vibration therapy applied to the knee extensors twice daily for 7 days
Study: 25290104
Drug: Stretching and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching and sports massage (SSM) performed twice daily for 7 days
Study: 23272987
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy and Enhanced treatment as usual
Study: 12897045
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (beta-carotene: 6 mg, vitamin C: 120 mg, vitamin E: 30 mg, zinc: 20 mg, selenium: 100 micro g)
Study: 10726050
Drug: 75 U
Normalized name: vitamin E 75 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 U anti‐Xa/kg BW (actual range 63 to 91) once daily started 12 hours before operation
Study: 10726050
Drug: 50 U
Normalized name: lipase 650 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 U anti‐Xa/kg BW (actual range 41 to 71) once daily started 2 hours before operation
Study: 1439060
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (active treatment)
Study: 1439060
Drug: Acupuncture (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (active treatment)
Study: 3803821
Drug: Zinc sulfate,
Normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc sulfate, 200 mg daily for 2 months
Study: 25061313
Drug: Ramipril-based therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril-based therapy
Study: 18160685
Drug: Defibrillator implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator implantation plus adjunctive catheter ablation
Study: 12479190
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI at 19 ng x ml(‐1) reduced to 10 ng x ml(‐1) after 1 min
Study: 12479190
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI at 15 ng x ml(‐1) reduced to 8 ng x ml(‐1) after 1 min
Study: 12479190
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI at 11 ng x ml(‐1) reduced to 6 ng x ml(‐1) after 1 min
Study: 12479190
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI at 6.5 microg x ml(‐1) reduced to 3 microg x ml(‐1) after 1 min
Study: 7926230
Drug: Cefuroxime 1500
Normalized name: cefuroxime 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1500 mg
Study: 7926230
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg
Study: 9222726
Drug: Undetectable total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undetectable total IgA (< 0.07 g/l) as a selection criterion for small bowel biopsy
Study: 3630597
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of bupivacaine-adrenaline solution (10 or 20 ml of 2.5 mg/ml or 5 mg/ml)
Study: 3630597
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of bupivacaine-adrenaline solution
Study: 29020861
Drug: High-dose psilocybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with standard support (HD-SS)
Study: 29020861
Drug: High-dose psilocybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with high support (HD-HS)
Study: 29020861
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose psilocybin (1 mg/70 kg) with standard support (LD-SS)
Study: 26928904
Drug: Low-equol group
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-equol group (10 mg/d)
Study: 26928904
Drug: High-equol group
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-equol group (20 mg/d)
Study: 22744655
Drug: Hematoma growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematoma growth (absolute increase of 10.7 mL over 24 hours)
Study: 22744655
Drug: Hematoma growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematoma growth (1 mL increase)
Study: 10373769
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid
Study: 7149895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three procedures
Study: 25342290
Drug: Modufolin® (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modufolin® (60 mg/m²)
Study: 25342290
Drug: Modufolin® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modufolin® (200 mg/m²)
Study: 25342290
Drug: Isovorin® (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovorin® (60 mg/m²)
Study: 25342290
Drug: Isovorin® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovorin® (200 mg/m²)
Study: 22640677
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment (treated group)
Study: 16463043
Drug: Multi-component physical
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component physical conditioning programme (supervised resistance, aerobic, and balance exercises twice per week, plus home-based exercises once per week)
Study: 16463043
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activities (Control group)
Study: 15243747
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of factors (BL, body mass, active drag factor, passive torque, drag efficiency, hydrostatic lift)
Study: 31087075
Drug: Zolbetuximab-chemotherapy combination
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab-chemotherapy combination
Study: 10225539
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 25% metronidazole gel
Study: 10225539
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (amoxicillin plus clavulanic acid 1 g/day for 14 days)
Study: 27191794
Drug: Intermediate-acting insulin
Normalized name: Intermediate-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-acting insulin (IMI)
Study: 27191794
Drug: Sliding-scale insulin
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding-scale insulin (SSI)
Study: 17766603
Drug: Acid buffering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid buffering gel plus diaphragm
Study: 15045133
Drug: Substitution of
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution of unfractionated heparin by low-molecular-weight heparins for regular anticoagulation
Study: 11573534
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of thiopental
Study: 9778007
Drug: Fentanyl and
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl and Propofol combination
Study: 3198983
Drug: Aminozolamide suspension
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aminozolamide suspension
Study: 3198983
Drug: Aminozolamide gel
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aminozolamide gel formulation
Study: 31815582
Drug: FOLFOX (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin)
Study: 12809582
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (NT)
Study: 10819341
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b capsular polysaccharide‐tetanus protein conjugate vaccine
Study: 31473690
Drug: Risk-reduction measures
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-reduction measures (e.g., checking air-quality forecasts, limiting outside activities)
Study: 24647431
Drug: Pain (induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain (induced by hypertonic saline injection) during bilateral leg squat task
Study: 20473057
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 25 mg eq.
Study: 20473057
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 150 mg eq.
Study: 20473057
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (all doses combined)
Study: 781661
Drug: Fluocinonide ('Metosyn')
Normalized name: Fluocinonide
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide ('Metosyn') applied once daily
Study: 781661
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate ('Betnovate') applied twice daily
Study: 18824271
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (EXU; Exubera)
Study: 18824271
Drug: Short-acting subcutaneous
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting subcutaneous (SC) insulin
Study: 15919435
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day)
Study: 15919435
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day) + steroids
Study: 12768289
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15.1 mg, treated once daily orally from 3 days before PRK to 1 month after PRK
Study: 12768289
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with LA and GLA)
Study: 10814990
Drug: 0.8-fold dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8-fold dose of protamine (Group L)
Study: 10814990
Drug: 2.0-fold dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0-fold dose of protamine (Group H)
Study: 1519637
Drug: Diltiazem (120,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120, 240, 360, or 480 mg)
Study: 1519637
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg/day for 2 weeks, 360 mg/day for 2 weeks, and then 540 mg/day for 2 weeks)
Study: 6501124
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 g latamoxef (moxalactam)
Study: 6501124
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of latamoxef (moxalactam)
Study: 25233856
Drug: TRK‐100STP 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK‐100STP 60 μg b.i.d.
Study: 25233856
Drug: TRK‐100STP 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK‐100STP 120 μg b.i.d.
Study: 22336172
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of rye bread (99 g/d to 198 g/d)
Study: 21163113
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg to 120 mg once daily
Study: 21163113
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg once daily
Study: 11077224
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) therapy
Study: 10464707
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: IFN (alpha Interferon‐1,000,000 U/d), Cyclosporine A (CSA‐1 mg/kg/d intravenous) for 28 days, and GM‐CSF (250/m2/d) until engraftment
Study: 10464707
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: CSA (1 mg/kg/d intravenous) and GM‐CSF
Study: 10464707
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: CSA (1 mg/kg/d orally) and GM‐CSF
Study: 7717013
Drug: Diltiazem (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (3 x 60 mg daily)
Study: 7717013
Drug: Metoprolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (3 x 50 mg daily)
Study: 29924771
Drug: Atorvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin therapy to achieve LDLC level less than 1.8 mmol/l
Study: 29924771
Drug: Therapy to
Normalized name: COOL THERAPY Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy to achieve LDLC level below 2.6 mmol/l
Study: 27145207
Drug: Soy food
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy food supplementation (50 mg isoflavones or 15 g soy protein in the form of tofu)
Study: 20860662
Drug: VS411-2 formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS411-2 formulation (didanosine 400 mg and hydroxyurea 600 mg)
Study: 18082885
Drug: Orbital radiation
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiation treatment
Study: 9230329
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (500 mg twice daily for 10 days)
Study: 3112672
Drug: No peritreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peritreatment antibiotics (from previous study)
Study: 9846530
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and prednisone (double-drug therapy)
Study: 9846530
Drug: Tacrolimus, prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Study: 22248502
Drug: BEET (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEET (140 ml/d of concentrated beetroot juice; 8 mmol/d nitrate)
Study: 11781274
Drug: CNI-1493 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-1493 (8 mg/m2 daily for 12 days)
Study: 11781274
Drug: CNI-1493 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-1493 (25 mg/m2 daily for 12 days)
Study: 2682877
Drug: Home continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home continuous intravenous infusion chemotherapy (CVI)
Study: 2682877
Drug: Inpatient continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient continuous intravenous infusion chemotherapy (CVI)
Study: 5354851
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate (tablets)
Study: 30376388
Drug: Massage (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage (20 min, twice a week for 12 weeks)
Study: 25483979
Drug: 5-day discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day discontinuation of statin treatment
Study: 25483979
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of statin treatment
Study: 24085590
Drug: Tizanidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine nasal spray (32.73 mg/mL) at doses of 2 mg and 4 mg
Study: 24085590
Drug: Tizanidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine nasal spray (16.36 mg/mL) at a dose of 1 mg
Study: 24085590
Drug: Tizanidine oral
Normalized name: tizanidine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine oral tablets (4 mg)
Study: 21943084
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy self management programme administered by a clinical psychologist over six consecutive weekly sessions (2 hours each)
Study: 21943084
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (atypical analgesia and local anaesthetic injections)
Study: 21943084
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy self management programme
Study: 19068785
Drug: Bisphosphonates (alendronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (alendronate, risedronate) and raloxifene (selective estrogen receptor modulator)
Study: 19068785
Drug: Pharmacotherapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy based on fracture risk factors
Study: 19068785
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for glucocorticoid- and diabetes mellitus-induced osteoporosis
Study: 12606904
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drug concentrations (propofol and remifentanil)
Study: 8708127
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 50 mg/kg with hydroxyzine 25 mg (Group 1)
Study: 8708127
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg/kg with acetaminophen elixir 10 mg/kg (Group 2)
Study: 28121797
Drug: Immediate feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate feeding (IF) with CHO + PRO (1.5 g·kg BM dextrose and 0.5 g·kg BM whey) ingested immediately postexercise.
Study: 28121797
Drug: Delayed feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed feeding (DF) with PLA ingested immediately postexercise and CHO + PRO solution 2 h postexercise.
Study: 28121797
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) solution ingested immediately and 2 h postexercise.
Study: 24979556
Drug: Probiotics (combination)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (combination)
Study: 19233930
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (3M Espe)
Study: 17768467
Drug: Rocuronium Bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium Bromide 1 mg/kg
Study: 3158243
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg/kg
Study: 31764782
Drug: Yiqi Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huayu Jiedu decoction (YHJD) combined with chemotherapy
Study: 25888414
Drug: beta‐guanidinopropionic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐guanidinopropionic acid 100 mg
Study: 12053590
Drug: Triamcinolone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (400 mg)
Study: 11761821
Drug: Formoterol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (24 mg)
Study: 9418312
Drug: Interpleural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural block with 0.4 ml/kg bupivacaine, 0.5% before induction of general anesthesia, followed by continuous administration of bupivacaine 0.25%, 0.125 ml/kg/hr.
Study: 2477909
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg)
Study: 3306380
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg nightly for 7 to 10 nights (abrupt-withdrawal group)
Study: 3306380
Drug: Tapered-dosage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered-dosage of triazolam: 0.5 mg for 7 nights, 0.25 mg for 2 nights, 0.125 mg for 2 nights (tapered-dosage group)
Study: 3306380
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial treatment for both groups)